Company Information
CIN
Status
Date of Incorporation
07 January 1984
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
27 July 2023
Paid Up Capital
128,298,890
Authorised Capital
440,000,000
Directors
Abhijit Ajay Majumdar
Manager/Secretary
about 2 years ago
about 2 years ago
Prasad Raghava Menon
Director/Designated Partner
about 2 years ago
about 2 years ago
Pallavi Joshi Bakhru
Director/Designated Partner
over 2 years ago
over 2 years ago
Sugata Sircar
Director/Designated Partner
over 2 years ago
over 2 years ago
Ramamohan Davuluri Rao
Director/Designated Partner
over 2 years ago
over 2 years ago
Homi Rustam Khusrokhan
Director/Designated Partner
almost 7 years ago
almost 7 years ago
Bharati Rao
Director/Designated Partner
over 11 years ago
over 11 years ago
Saharsh Rao Davuluri
Director/Designated Partner
over 16 years ago
over 16 years ago
Sucheth Rao Davuluri
Director/Designated Partner
over 22 years ago
over 22 years ago
Parampally Vasudeva Maiya
Director/Designated Partner
over 26 years ago
over 26 years ago
Shashi Bhushan Budhiraja
Director
almost 29 years ago
almost 29 years ago
Past Directors
Amit Agarwal
Cfo(kmp)
about 8 years ago
about 8 years ago
Nirmala Srinivasa Murthy
Additional Director
over 10 years ago
over 10 years ago
Viswanathan Nelluvaya Subrahmanian Iyer
Cfo(kmp)
over 11 years ago
over 11 years ago
Nadeem Askari Panjetan
Nominee Director
over 14 years ago
over 14 years ago
Christopher Cimarusti M
Additional Director
about 16 years ago
about 16 years ago
William Gordon Mitchell
Director
over 17 years ago
over 17 years ago
Lakshmi Kakumani Sandhya
Company Secretary
almost 18 years ago
almost 18 years ago
Natesan Balakrishna Iyer
Nominee Director
over 28 years ago
over 28 years ago
Humayun Dhanrajgir
Director
over 31 years ago
over 31 years ago
Patents
The present invention is directed to a novel, industrially viable, cost effective process for manufacturing (5S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide going through a novel intermediate of Formula XXI and XXII.
AN IMPROVED PROCESS FOR PREPARATION OF OLANZAPINE PAMOATE
An improved process for preparation of Olanzapine pamoate monohydrate from Olanzpaine is disclosed which comprises mixing at room temperature a solution of Olanzapine prepared in water in presence of an acid, with a solution of pamoic acid prepared in wate...
AN IMPROVED PROCESS FOR PREPARATION OF SUGAMMADEX SODIUM
The present invention provides a process for the preparation of Sugammadex sodium involving the step of: reacting 6-perdeoxy-6-per-halo-gamma-cyclodextrin with 3-mercapto propionic acid in the presence of alkali metal alkoxide in an organic solvents. The inve...
The present invention is directed to a novel, facile, concise, industrially viable and cost effective process for the preparation of (5-Nitro-4-thiocyanate pyrimidinl)-3H-benzo(d)-imidazolyl-5-carbonitrile a compound of formula I.
The present invention is directed to a novel, industrially viable and cost effective process for manufacturing (3S)-1 -[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-a,a-diphenyl-3-pyrrolidineacetamide hydrobromide also known as Darifenacin hydrobromide
The present invention relates to process for the preparation of enantiomerically pure (S,S)-2,8-Diazabicyclo [4.3.0] nonane of Formula I and consequent conversion to Moxifloxacin hydrochloride monohydrate.
The present invention relates to a novel, industrially viable and cost effective process for preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, commonly known as Rosuvastatin calcium.
The present invention is directed to an novel, industrially viable and cost effective process for preparation of substantially pure form of 2-butyl-3-[[2"-(lH-tetrazol-5-yl)[l,1-biphenyl]-4-yl]methyl]-l,3-diazaspiro[4.4]non-l-en-4-one commonly known as Irbesartan.
The present invention relates to a simple and efficient method for manufacturing stable anhydrous form B of substantially pure (la,2B,4B,5a,7B)-7-[(hydroxydi-2-thienylacteyl)oxy]-
2,,4
9,9-dimethyl-3-oxa-9-azaniatricyclo[3.3.1.0 ' ] nonane-bromide i.e. Tiotropium bromide, with a purity level of 99.99% and which is...
The present invention relates to a novel, industrially viable and cost effective process for manufacturing of substantially pure anhydrous Form B of 7-[4-[4-(2,3-dichlorophenyl)-l-piperazinyl]butoxy]-3,4-di-hydrocarbostyril also known as Aripiprazole
The present invention is directed to an novel, industrially viable and cost effective process for preparation of substantially pure N-[[trans-4-(l-methylethyl) cyclohexyl] carbonyl]-D-phenylalanine commonly known as Nateglinide.
The present invention encompasses the method of purification of Darifenacin
Hydrobromide
using purified water and its process for preparation using novel intermediates.
The present invention relates to a simple efficient and cost effective process for commercial manufacture of (E)-3-[2-Butyl-l-{(4-carboxyphenyl) methyl}-IH-imidazole-5-yl]-2-(thiophen-2-ylmethyl)prop-2-enoic acid and its conversion to substantially pure anhydrous mesylate salt with a purity level of 99.85% and singl...
The present invention relates to a novel industrially viable, cost effective process to manufacture substantially pure form of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1 -(1H-1,2,4-triazol-l-yl)butan-2-ol (Voriconazole) with a chiral purity level of greater than 99.9% and impurity level of less than...
The present invention relates to a novel, industrially viable and cost effective process for preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, commonly known as Rosuvastatin calcium.
The present invention encompasses a process for the preparation and purification of cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methxoy]phenyl]-1 -piperazinyl]phenyl]-2,4-dihydro-2-( 1 -methylpropyl)-3H-1,2,4-triazol-3-one of formula I to obtain a specifically desired fo...
The present invention relates to an improved, cost effective, eco-friendly and easy to handle process to manufacture substantially pure form of (2E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide or (E)- N,N-diethyl-2-cyano-3-(3,4-dihyroxy-5-nitrophenyl)-acrylamide polymorphic form A commonly know...
The present invention is directed to an improved industrially viable, cost effective process to manufacture substantially pure form of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-l-(lH-l,2,4-triazol-l-yl)butan-2-ol (Voriconazole) with a chiral purity level of greater than 99.9% and impurity level of le...
The present invention is directed to an improved industrially viable, cost effective process for manufacturing pure racemic crystalline anhydrous form of (l-benzyl-4-(5,6,-dimethoxyindanone-2yl)methylpiperidine) hydrochloride Form III commonly known as Donepezil hydrochloride with a purity level of greater than 99.9...
The present invention relates to a simple efficient and cost effective process for commercial manufacture of (E)-3-[2n-butyl-l-((4-carboxyphenyl) methyl}-lH-imidazole-5-yl]-(2-thienyl)methyl"2-propenioc acid and its conversion to substantially pure anhydrous mesylate salt as shown in Formula I, with a purity level o...
ABSTRACT
The present invention relates to an improved simple, efficient and cost effective process for the commercial manufacture of (αS)-α-Ethyl-2-oxo-l-pyrrolidineacetamide and improved processes for the preparation thereof.
An improved process for the preparation of Elagolix Sodium having the structural formula (I).
The present invention relates the novel intermediates useful in the preparation of Elagolix Sodium.
An improved process for the preparation 2-aminobutyramide of formula (I) by continuous flow technology.
The above intermediate of formula (I) is to provide process with lower operational expenditure, higher yield and higher purity.
The compound of formula (I) is used as an intermediate in the synthesis of...
Abstract
An improved process for the preparation of Brivaracetam having the structural formula (I).
Improved process for the preparation of Liraglutide having the structural formula (I).
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Glu-Palmitoyl)-Glu-Phe-lle-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Formula-I
The present invention relates to novel fragments-2 and -4 which are us...
Novel process for the preparation of Brivaracetam having the structural formula (I).
The present invention also provides a novel compound of formula (IV).
wherein X is a halogen and R is alkyl, cycloalkyl, alkoxy, aryloxy, aryl or alkylaryl.
The present invention also provides process for the pr...
The present invention provides a process for the preparation of Lacosamide impurities.
The present invention provides a process for the preparation of Indacaterol acetate of Formula-I,
The present invention also provides a novel crystalline form of Indacaterol acetate.
The present application relates to supra-molecular complex of valsartan and sacubitril which is known as LCZ696 and process for the preparation thereof.
The present invention discloses a process for the preparation of Sacubitril of Formula I and its novel intermediates.
The present invention provides a process for the preparation of (5-(4-cyanophenoxy)-l-hydroxy-l,3- dihydro-2, l-benzoxaborole having formula (I).
The present invention relates to an improved process for the preparation of Sugammadex sodium of formula-(I)
(I)
The present invention relates to a process for large scale liquid phase synthesis of Octreotide acetate of formula (I).
The invention also relates to process of preparation of novel intermediates of formula (A), formula (B) and formula (C) used in the synthesis of Octreotide acetate of formula (I).
...
The present invention relates to commercial scale manufacturing process for the preparation of 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro carbostyril monohydrate having formula (I).
ABSTRACT
The present invention provides a process for the preparation of Itraconazole intermediate compound of formula I
The present invention relates to an improved process for the preparation of (5-(4-cyanophenoxy)-l-hydroxy-l,3- dihydro-2, l-benzoxaborole having formula (I).
(I)
The present invention also relates to novel intermediates which is useful in the preparation of Crisaborole of formula-I.
...
An improved process for the preparation of Elagolix Sodium having the structural formula (I).
The present invention relates the novel intermediates and salts useful in the preparation of Elagolix Sodium.
An improved process for the preparation of Indacaterol Maleate having the structural formula (I).
The present invention also relates to an improved process for the preparation of benzyl intermediate of Formula IV.
An improved process for the preparation of Mirtazapine having the structural formula (I).
The present invention relates the novel intermediate of formula (V), which is useful in the preparation of Mirtazapine.
(V)
Abstract
The present invention relates to improved process for the preparation of 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril monohydrate having formula (I).
The present invention relates to an improved process for the preparation of Vilanterol trifenatate having the structural formula-I using novel succinate salt of Vilanterol intermediate.
The present invention also relates to novel succinate salt of Vilanterol intermediate having the structural formula-V and proce...
An improved process for the preparation of Elagolix Sodium having the structural formula (I).
The present invention relates to highly pure compound of formula-VI as a solid which is useful in the preparation of Elagolix sodium.
The present invention provides a stable, simple and commercially viabl...
An improved proves for the preparation of Tafamidis meglumine having the structural formula I.
The present invention also provides an improved process for the preparation of Tafamidis of formula Ia.
The present invention also provides an improved process for the preparation of Tafamidis intermediate of f...
Improved process for the preparation of Semaglutide having the structural formula (I).
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys (C18 di acid mono-t-butyl-?-Glu(AEEA-AEEA)-OtBu)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Formula-I
The present invention relates to the...
The present invention relates to a novel crystalline Form-N of Tafamidis free acid of formula I.
The present invention also relates to a process for the preparation of novel crystalline form-N of
Tafamidis free acid of formula-I.
Abstract
The present invention relates to an improved process for the preparation of Tapinarof compound of Formula-I.
which comprises:
Reacting of Methyl 3,5-dimethoxy benzoate compound of Formula-1 with Isopropanol to obtain Methyl 3,5-dimethoxy-4-isopropylbenzoate compound of Formula-2; reduction of Methyl 3...
Abstract
Improved process for the preparation of Semalinker having the structural formula (I).
Formula-I
The present invention also relates to the following fragments which are useful in the preparation of Semalinker.
Fragment-1: Fmoc-Lys(AEEA-NH2)-OH
Fragment-2: Z-Glu(AEEA-OSu)-OtBu
Fragment-3: OtB...
The present invention relates to an improved process for the preparation of Finerenone compound of Formula-I.
The present invention also relates to novel intermediate compounds of Formula-IV, VI, VII & VIII used in the preparation of Finerenone compound of Formula-I
The present invention also ...
The present invention relates to an improved process for the preparation of Tapinarof compound of Formula-I.
The present invention also relates to novel intermediate compound of Formula-5 used in the preparation of Tapinarof compound of Formula-I
The present invention also relates to process for the ...
The present invention relates to Adipic acid cocrystals of Voxelotor of Formula I.
I
The present invention also relates process for the preparation of Adipic acid cocrystals of Voxelotor.
Abstract
An improved process for the preparation of Roxadustat having the structural formula I.
The present invention also provides a process for the preparation of Roxadustat intermediate having the structural formula Ia.
The present invention relates to an improved process for the preparation of Tapinarof compound of Formula – I.
Which comprises:
Reacting of Methyl 3,5-dimethoxy benzoate compound of Formula-1 with Isopropanol to obtain Methyl 3,5-dimethoxy-4-isopropylbenzoate compound of Formula-2; reacting Methyl 3,5-dimethoxy...
The present invention discloses an improved process for the preparation of Difelikefalin Acetate having the structural Formula I.
Formula I
The present invention also discloses novel intermediate compounds of Formula IIIb, Formula IVb, Formula Vb and Fragment 2, and their preparation processes.
wherein, R2...
An improved process for the preparation of Tirzepatide having the chemical structural Formula I.
The present invention also relates to novel Fragments-2, 3, 4, 5 and its process of preparation.
The present invention also relates to novel compounds of Formulae II, III, IIIa, V, Va and its pro...
Abstract
An improved process for the preparation of Tirzepatide by a linear synthesis having the chemical structural Formula I.
The present invention also relates to novel intermediates of Formula II, III and its process for preparation.
Formula II: Boc- Tyr(tBu)-Aib-Glu(OtBu)-Gly-Thr(tBu)-Phe-Thr(tBu)-...
Abstract
Improved process for the preparation of Difelikefalin Acetate having the structural Formula I.
which comprises: anchoring Boc-Pip(Fmoc)-OH to a resin in presence of a base, coupling of Fmoc-D-Lys(Boc)-OH to a resin in presence of coupling agent in a solvent to obtain dipeptide resin followed by sequ...
Abstract
The present invention relates to an improved process for the preparation of sterile Brinzolamide compound of Formula-I by using Aluminium Canister and Aluminium foil.
The present invention also relates to an improved process for the preparation of sterile Brinzolamide compound of Formula-I by usin...
The present invention relates to an improved process for the preparation of Finerenone compound of Formula I.
The present invention also relates to novel intermediate compounds of Formula II, III IV, V & VI and its process for the preparation.
An improved process for the preparation of Edaravone of Formula I, comprising the steps of:
i) reacting the phenyl hydrazine with ethyl acetoacetate in methanol and water as solvent, triethylamine as base to obtain a reaction mass containing Edaravone;
ii) isolating Edaravone from the reaction mass obtained in ste...
Abstract
An improved process for the preparation of Tirzepatide having the chemical structural Formula I.
The present invention also relates to the compounds of SEQ ID NO. 1 to 14 or a pharmaceutically acceptable salt thereof for use in the synthesis of Tirzepatide or a pharmaceutically acceptable salt thereof....
The present invention relates to an improved process for the preparation of Edoxaban Tosylate of compound of Formula I.
Which comprises:
Condensation of 2-Amino-5-chloropyridine compound of Formula-2 with Ethyl oxalyl chloride of Formula-3 to obtain Ethyl 2-((5-chloropyridin-2-yl) amino)-2-oxoacetate compou...
An improved process for the preparation of (S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine(2R,3R)-2,3 bis(benzoyloxy) succinic acid compound of Formula I.
Imine formation of compound of Formula II with n-propylamine and acetic acid in presence of methanol to obtain compound of Formula III. Reduct...
Abstract
The present invention relates to process for the preparation of Tapinarof form-1 from Tapinarof form-II by dissolving in methanol and water.
Abstract
The present invention relates to an improved process for the preparation of Tapinarof compound of Formula-I.
Which comprises:
Reacting of 3,5-dihydroxy-4-isopropylbenzoic acid compound of Formula-1 with chloromethyl methyl ether (MOM-Cl) to obtain Methoxymethyl 4-isopropyl-3,5-bis (methoxymethyl) benz...
An improved process for the preparation of Rotigotine compound of Formula I with resolving agents.
Imine formation of compound of Formula II with n-propylamine and acetic acid in presence of solvent to obtain compound of Formula III(a). Reduction of compound of Formula IIIa with reducing agent to obtain co...
An improved process for the preparation of Edaravone of Formula I, comprising the steps of:
i) reacting the phenyl hydrazine with ethyl acetoacetate in methanol and water as solvent, triethylamine as base to obtain a reaction mass containing Edaravone;
ii) isolating Edaravone from the reaction mass obtained in ...
Abstract
The present invention relates to process for the preparation of Apixaban polymorphic form N-1 of formula (I) having a particle size diameter D90 greater than 90 µm with plate shape.
Abstract
Novel process for the preparation of Difelikefalin Acetate having the structural Formula I.
which comprises: activation of N-protected-D-Phe-OH in presence of activating agent followed by coupling with H-D-Phe-OH to obtain N-protected-D-Phe-D-Phe-OH dipeptide which is sequential activation and coupl...
Registered Trademarks
[Class : 1] Chemical Used In Industry[Class : 5] Pharmaceutical Products, Dietetic Substances Adapted For Medical Use[Class : 9] Scientific, Optical, Life Saving Apparatus And Instruments; And Data Processing Equipment
[Class : 1] Chemical Used In Industry[Class : 5] Pharmaceutical Products, Dietetic Substances Adapted For Medical Use[Class : 9] Scientific, Optical, Life Saving Apparatus And Instruments; And Data Processing Equipment
[Class : 1] Chemical Used In Industry[Class : 5] Pharmaceutical Products, Dietetic Substances Adapted For Medical Use[Class : 9] Scientific, Optical, Life Saving Apparatus And Instruments; And Data Processing Equipment
View +20 more Brands for Neuland Laboratories Ltd..
Charges
29 June 2018
Aditya Birla Finance Limited
25 Crore
23 June 2016
Rbl Bank Limited
16 Crore
04 December 2015
Indusind Bank Ltd.
75 Crore
21 October 2011
State Bank Of India
351 Crore
21 October 2011
State Bank Of India
207 Crore
10 June 2013
State Bank Of India
207 Crore
27 June 2014
Bank Of India
20 Crore
01 December 2016
State Bank Of India
306 Crore
23 September 2014
Kotak Mahindra Bank Limited
15 Crore
31 March 2017
State Bank Of India
10 Crore
30 December 2015
Hero Fincorp Limited
25 Crore
28 March 2016
Punjab National Bank
17 Crore
27 June 2014
Bank Of India
20 Crore
28 September 2011
Export-import Bank Of India
10 Crore
01 October 2010
Sbi Global Factors Limited
5 Crore
19 December 2007
Export-import Bank Of India
30 Crore
23 January 2010
State Bank Of India
22 Crore
04 March 1986
State Bank Of India
150 Crore
29 October 2014
The Ratnakar Bank Limited
20 Crore
07 February 2007
Export-import Bank Of India
36 Crore
28 March 2008
Bank Of India
31 Crore
27 September 2008
Bank Of India
12 Crore
12 January 1993
The Industrial Credit & Investment Corporation Of India Ltd.
2 Crore
27 December 1994
The Industrial Credit & Investment Corporation Of India Ltd.
3 Crore
05 January 2004
Indian Overseas Bank
17 Crore
04 April 2002
Bank Of India
23 Crore
04 March 1986
State Bank Of India
85 Crore
29 October 1988
State Bank Of India
68 Lak
05 May 1988
State Bank Of India
15 Lak
22 December 2001
Technology Information Forecasting & Assessment Council
1 Crore
27 January 2004
Lakshmi Vilas Bank
2 Crore
25 June 2007
Bank Of India
3 Crore
28 March 2005
Export-import Bank Of India
13 Crore
17 August 2006
Bank Of India
2 Crore
05 June 2009
Axis Bank
22 Crore
10 September 2004
The Karur Vysysa Bank Ltd.
6 Crore
22 August 2006
Lakshmi Vilas Bank
3 Crore
23 March 2006
Lakshmi Vilas Bank
2 Crore
25 September 2000
Industrial Development Bank Of India
6 Crore
10 February 2003
Indian Overseas Bank
2 Crore
20 December 2001
Uti Bank Limited
10 Crore
20 December 2001
Uti Bank Limited
10 Crore
28 September 1998
Industrial Development Bank Of India
5 Crore
03 May 2002
Bank Of Bahrain & Kuwait
2 Crore
12 November 1997
Export-import Bank Of India
60 Lak
21 April 1994
The Scici Limited
2 Crore
16 August 1995
The Industrial Credit & Investment Corporation Of India Ltd.
5 Crore
05 August 1989
A. P. Industrial Development Corporation Ltd.
25 Lak
08 January 1985
Andhra Pradesh Industrial Development Corporation
42 Lak
05 November 1984
Andhra Pradesh State Financial Corporation
30 Lak
02 September 1989
A. P. State Financial Corporation
22 Lak
31 January 1987
Andhra Pradesh State Financial Corporation
3 Lak
05 November 1984
Andhra Pradesh State Financial Corporation
30 Lak
29 August 2020
Kotak Mahindra Bank Limited
19 Crore
22 July 2020
Axis Bank Limited
42 Lak
21 July 2020
Hdfc Bank Limited
35 Crore
19 December 2019
Rbl Bank Limited
30 Crore
29 July 2022
Sbicap Trustee Company Limited
0
21 October 2011
State Bank Of India
0
29 August 2020
Others
0
24 September 2021
Others
0
29 June 2018
Others
0
19 December 2019
Others
0
21 July 2020
Hdfc Bank Limited
0
19 December 2007
Export-import Bank Of India
0
22 July 2020
Axis Bank Limited
0
31 March 2017
State Bank Of India
0
01 December 2016
State Bank Of India
0
23 March 2006
Lakshmi Vilas Bank
0
23 June 2016
Others
0
04 December 2015
Others
0
17 August 2006
Bank Of India
0
04 March 1986
State Bank Of India
0
05 May 1988
State Bank Of India
0
10 September 2004
The Karur Vysysa Bank Ltd.
0
20 December 2001
Uti Bank Limited
0
28 March 2005
Export-import Bank Of India
0
27 January 2004
Lakshmi Vilas Bank
0
05 January 2004
Indian Overseas Bank
0
04 April 2002
Bank Of India
0
22 December 2001
Technology Information Forecasting & Assessment Council
0
25 September 2000
Industrial Development Bank Of India
0
28 September 1998
Industrial Development Bank Of India
0
16 August 1995
The Industrial Credit & Investment Corporation Of India Ltd.
0
27 December 1994
The Industrial Credit & Investment Corporation Of India Ltd.
0
02 September 1989
A. P. State Financial Corporation
0
29 October 1988
State Bank Of India
0
31 January 1987
Andhra Pradesh State Financial Corporation
0
05 November 1984
Andhra Pradesh State Financial Corporation
0
05 November 1984
Andhra Pradesh State Financial Corporation
0
29 October 2014
The Ratnakar Bank Limited
0
27 June 2014
Bank Of India
0
27 June 2014
Bank Of India
0
27 September 2008
Bank Of India
0
01 October 2010
Sbi Global Factors Limited
0
04 March 1986
State Bank Of India
0
25 June 2007
Bank Of India
0
10 February 2003
Indian Overseas Bank
0
21 April 1994
The Scici Limited
0
30 December 2015
Hero Fincorp Limited
0
28 March 2016
Others
0
23 September 2014
Kotak Mahindra Bank Limited
0
12 January 1993
The Industrial Credit & Investment Corporation Of India Ltd.
0
03 May 2002
Bank Of Bahrain & Kuwait
0
05 August 1989
A. P. Industrial Development Corporation Ltd.
0
10 June 2013
State Bank Of India
0
21 October 2011
State Bank Of India
0
22 August 2006
Lakshmi Vilas Bank
0
28 September 2011
Export-import Bank Of India
0
12 November 1997
Export-import Bank Of India
0
23 January 2010
State Bank Of India
0
05 June 2009
Axis Bank
0
20 December 2001
Uti Bank Limited
0
28 March 2008
Bank Of India
0
07 February 2007
Export-import Bank Of India
0
08 January 1985
Andhra Pradesh Industrial Development Corporation
0
29 July 2022
Sbicap Trustee Company Limited
0
21 October 2011
State Bank Of India
0
29 August 2020
Others
0
24 September 2021
Others
0
29 June 2018
Others
0
19 December 2019
Others
0
21 July 2020
Hdfc Bank Limited
0
19 December 2007
Export-import Bank Of India
0
22 July 2020
Axis Bank Limited
0
31 March 2017
State Bank Of India
0
01 December 2016
State Bank Of India
0
23 March 2006
Lakshmi Vilas Bank
0
23 June 2016
Others
0
04 December 2015
Others
0
17 August 2006
Bank Of India
0
04 March 1986
State Bank Of India
0
05 May 1988
State Bank Of India
0
10 September 2004
The Karur Vysysa Bank Ltd.
0
20 December 2001
Uti Bank Limited
0
28 March 2005
Export-import Bank Of India
0
27 January 2004
Lakshmi Vilas Bank
0
05 January 2004
Indian Overseas Bank
0
04 April 2002
Bank Of India
0
22 December 2001
Technology Information Forecasting & Assessment Council
0
25 September 2000
Industrial Development Bank Of India
0
28 September 1998
Industrial Development Bank Of India
0
16 August 1995
The Industrial Credit & Investment Corporation Of India Ltd.
0
27 December 1994
The Industrial Credit & Investment Corporation Of India Ltd.
0
02 September 1989
A. P. State Financial Corporation
0
29 October 1988
State Bank Of India
0
31 January 1987
Andhra Pradesh State Financial Corporation
0
05 November 1984
Andhra Pradesh State Financial Corporation
0
05 November 1984
Andhra Pradesh State Financial Corporation
0
29 October 2014
The Ratnakar Bank Limited
0
27 June 2014
Bank Of India
0
27 June 2014
Bank Of India
0
27 September 2008
Bank Of India
0
01 October 2010
Sbi Global Factors Limited
0
04 March 1986
State Bank Of India
0
25 June 2007
Bank Of India
0
10 February 2003
Indian Overseas Bank
0
21 April 1994
The Scici Limited
0
30 December 2015
Hero Fincorp Limited
0
28 March 2016
Others
0
23 September 2014
Kotak Mahindra Bank Limited
0
12 January 1993
The Industrial Credit & Investment Corporation Of India Ltd.
0
03 May 2002
Bank Of Bahrain & Kuwait
0
05 August 1989
A. P. Industrial Development Corporation Ltd.
0
10 June 2013
State Bank Of India
0
21 October 2011
State Bank Of India
0
22 August 2006
Lakshmi Vilas Bank
0
28 September 2011
Export-import Bank Of India
0
12 November 1997
Export-import Bank Of India
0
23 January 2010
State Bank Of India
0
05 June 2009
Axis Bank
0
20 December 2001
Uti Bank Limited
0
28 March 2008
Bank Of India
0
07 February 2007
Export-import Bank Of India
0
08 January 1985
Andhra Pradesh Industrial Development Corporation
0
Documents
Form CHG-1-16022021-signed
CERTIFICATE OF REGISTRATION OF CHARGE-20210216
Form CHG-1-05112020_signed
Form CHG-1-04112020_signed
Instrument(s) of creation or modification of charge;-04112020
Particulars of all joint charge holders;-04112020
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201104
Form MSME FORM I-29102020_signed
Instrument(s) of creation or modification of charge;-28102020
Optional Attachment-(1)-28102020
Form CHG-1-27102020_signed
Instrument(s) of creation or modification of charge;-27102020
Optional Attachment-(1)-27102020
CERTIFICATE OF REGISTRATION OF CHARGE-20201027
Form MGT-14-01102020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-01102020
Optional Attachment-(3)-01102020
Optional Attachment-(1)-01102020
Evidence of cessation;-01102020
Form DIR-12-01102020_signed
Form GNL-2-15092020-signed
Optional Attachment-(1)-03092020
Optional Attachment-(1)-28082020
Optional Attachment-(2)-28082020
Form DIR-12-28082020_signed
Instrument(s) of creation or modification of charge;-18082020
Form CHG-1-18082020_signed
CERTIFICATE OF REGISTRATION OF CHARGE-20200818
List of share holders, debenture holders;-13082020
Form MGT-7-13082020_signed
